Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism

Authors Tellor K, Van Tuyl J, Armbruster A

Received 13 January 2016

Accepted for publication 26 February 2016

Published 26 April 2016 Volume 2016:12 Pages 667—674


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Katie B Tellor, Joseph S Van Tuyl, Anastasia L Armbruster

Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, USA

Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in 2015 for stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism. It is the fourth target-specific oral anticoagulant to be approved. Edoxaban is noninferior for efficacy compared to warfarin for both approved indications. Edoxaban is superior to warfarin for the first major or clinically relevant nonmajor bleeding event in venous thromboembolism and major bleeding in nonvalvular atrial fibrillation. Edoxaban is dosed once daily for both indications and requires dose adjustment for renal function. In patients with nonvalvular atrial fibrillation, use is not recommended in patients with a creatinine clearance greater than 95 mL/min due to reduced efficacy. Edoxaban offers a new therapeutic alternative to the currently available options in the market.

Keywords: anticoagulation, stroke, deep vein thrombosis, pulmonary embolism, atrial fibrillation, Savaysa™

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]